Oral p38 Mitogen-Activated Protein Kinase Inhibition With BIRB 796 for Active Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial
- 16 January 2006
- journal article
- research article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 4 (3) , 325-334
- https://doi.org/10.1016/j.cgh.2005.11.013
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's diseaseGut, 2004
- Tumour necrosis factor converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel diseaseGut, 2002
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialPublished by Elsevier ,2002
- Newly diagnosed rheumatoid arthritisAnnals of the Rheumatic Diseases, 2002
- Infliximab for the Treatment of Fistulas in Patients with Crohn's DiseaseNew England Journal of Medicine, 1999
- A Specific Inhibitor of the p38 Mitogen Activated Protein Kinase Affects Differentially the Production of Various Cytokines by Activated Human T Cells: Dependence on CD28 Signaling and Preferential Inhibition of IL-10 ProductionCellular Immunology, 1999
- Inhibition of Thl responses prevents inflammatory bowel disease in scid mice reconstituted with CD45RBhi CD4+ T cellsPublished by Elsevier ,1994
- Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease.Gut, 1993
- Enhand secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's diseaseClinical and Experimental Immunology, 1993
- Interleukin-10-deficient mice develop chronic enterocolitisCell, 1993